Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Autor: Laura Ciaffi, Sinata Koulla-Shiro, Adrien Bruno Sawadogo, Cheik Tidiane Ndour, Sabrina Eymard-Duvernay, Pretty Rosereine Mbouyap, Liliane Ayangma, Jacques Zoungrana, Ndeye Fatou Ngom Gueye, Mohamadou Diallo, Suzanne Izard, Guillaume Bado, Coumba Toure Kane, Avelin Fobang Aghokeng, Martine Peeters, Pierre Marie Girard, Vincent Le Moing, Jacques Reynes, Eric Delaporte, J Reynes, E Delaporte, S Koulla-Shiro, CT Ndour, AB Sawadogo, M Seidy, V Le Moing, A Calmy, L Ciaffi, NF Ngom Gueye, PM Girard, S Eholie, JB Guiard-Schmid, ML Chaix, C Kouanfack, I Tita, B Bazin, P Garcia, S Izard, S Eymard-Duvernay, M Peeters, L Serrano, A Cournil, PR Mbouyap, R Toby, N Manga, L Ayangma, M Mpoudi, Ngole J Zoungrana, M Diallo, AF Aghokeng, E Guichet, O Bell, H Abessolo Abessolo, MR Djoubgang, G Manirakiza, G Lamarre, T Mbarga, S Epanda, A Bikie, T Nke, N Massaha, E Nke, D Bikobo, J Olinga, O Elat, A Diop, B Diouf, N Bara, MB Koita Fall, C Toure Kane, FB Seck, S Ba, P Njantou, A Ndyaye, P Fao, R Traore, Y Sanou, G Bado, M Coulibaly, E Some, J Some, A Kambou, A Tapsoba, D Sombie, S Sanou, B Traore, P Flandre, C Michon, J Drabo, F Simon

Publikováno v: Lancet HIV
Lancet HIV, 2017, 4 (9), pp.e384--e392. ⟨10.1016/S2352-3018(17)30069-3⟩
Lancet HIV, Elsevier, 2017, 4 (9), pp.e384--e392. ⟨10.1016/S2352-3018(17)30069-3⟩

Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e134a5a3ec01e9f053cb6a49d0a556f0
https://hal.science/hal-01761365